Alglucosidase Alfa (Lumizyme)

Lumizyme (alglucosidase alfa) is covered only for Pompe disease (acid α‑glucosidase deficiency) and is not covered for non‑FDA indications. Approval (up to 12 months) requires confirmed diagnosis by deficient enzyme activity in blood/fibroblasts/muscle or by molecular genetic testing, prescription by or consultation with a geneticist/neurologist/metabolic or lysosomal storage disorders specialist, and dosing limited to 20 mg/kg IV no more frequently than every 2 weeks.

"Lumizyme (alglucosidase alfa) is indicated for the treatment of individuals with Pompe disease (acid α-glucosidase deficiency)."

Sign up to see full coverage criteria, indications, and limitations.